A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration ‐resistant prostate cancer

ConclusionsTreatment with abiraterone acetate without steroids is feasible, although clinically significant adverse events can occur in a minority of patients. The use of abiraterone acetate without prednisone should be balanced with the potential for toxicity and requires close monitoring.

Source: Cancer - November 14, 2018 Category: Cancer & Oncology Authors: Rana R. McKay, Lillian Werner, Susanna J. Jacobus, Alexandra Jones, Elahe A. Mostaghel, Brett T. Marck, Atish D. Choudhury, Mark M. Pomerantz, Christopher J. Sweeney, Susan F. Slovin, Michael J. Morris, Philip W. Kantoff, Mary ‐Ellen Taplin Tags: Original Article Source Type: research